Sagimet Biosciences Inc.SGMTEarnings & Financial Report
Nasdaq
SGMT Q3 2023 Key Financial Metrics
Revenue
$2.0M
Gross Profit
N/A
Operating Profit
$-7.5M
Net Profit
$-6.4M
Gross Margin
N/A
Operating Margin
-372.6%
Net Margin
-317.6%
YoY Growth
N/A
EPS
$-0.35
Financial Flow
Sagimet Biosciences Inc. Q3 2023 Financial Summary
Sagimet Biosciences Inc. reported revenue of $2.0M for Q3 2023, with a net profit of $-6.4M (-317.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $2.0M |
|---|---|
| Net Profit | $-6.4M |
| Gross Margin | N/A |
| Operating Margin | -372.6% |
| Report Period | Q3 2023 |
Income Statement
| Q3 2023 | |
|---|---|
| Revenue | $2.0M |
| YoY Growth | N/A |
Balance Sheet
| Q3 2023 | |
|---|---|
| Assets | $102.9M |
| Liabilities | $5.0M |
| Equity | $97.9M |
Cash Flow
| Q3 2023 | |
|---|---|
| Operating CF | $-3.9M |